Genedata Partners with Cergentis to Provide End-to-end Solution for Automating TLA-based Clone Selection
Genedata Selector automates sample management, data analysis and report generation for high-throughput Targeted Locus Amplification (TLA) workflow
April 28, 2020
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the availability of Genedata Selector® for automating the Targeted Locus Amplification (TLA) data analysis workflow. The software solution is the result of a close collaboration with Cergentis, an innovative leader in the genomics space and the developer and provider of the TLA technology, together with joint customers in the biopharmaceutical industry.
The cutting-edge TLA technology is used during cell line development to standardize and speed up the clone selection process. With TLA, Cergentis provides a cost-efficient, high resolution technology to determine transgene integration sites and detect single nucleotide and structural variants in the transgene sequence, as well as structural changes in and surrounding transgene sequences. This information is highly relevant to quickly assess the quality of cell line clones during cell line development. TLA also detects sequence changes resulting from targeted genome editing (such as CRISPR) and/or targeted transgene integrations.
As the technology is now being implemented in many biopharmaceutical R&D organizations to speed and scale up the experimental throughput, the need has emerged for a scalable computational solution that allows customers to rapidly analyze their own TLA data to accelerate decision making during the cell line development process. Besides scalability, key requirements for such a computational solution are workflow integration from sample registration to reporting, plus ease of use from the perspective of a scientist.
Genedata Selector is the first-in-class software platform that satisfies these key requirements. Providing an end-to-end solution, it offers sample registration capabilities and includes the option of full automation of the highly complex sequence data analysis process. Intuitive visualizations enable quick decision making and can be easily integrated into reports used for regulatory purposes.
Highly cost- and time-efficient, Genedata Selector:
- offers full automation of the data analysis workflow, speeds up complex analysis workflows, enables high experimental throughput, and delivers data analysis results without the need for special data analysis expertise;
- maintains a full track record of analyzed clones, including clone hierarchies, with audit trail functionality that allows deployment in a regulatory-compliant environment;
- reduces by orders of magnitude the analysis time from project initiation to reporting of results;
- can be deployed on premises as well as under a Managed SaaS model.
“Genedata developed a push button system including a fully integrated analysis pipeline, to allow our customers in cell line development to get a comprehensive analysis report, including visual representation of integration sites,” said Max van Min, Founding Director of Cergentis. “Our customers now have available a computational platform that supports our market-leading TLA technology and enables them to significantly increase the number of clones analyzed, thereby increasing the efficiency of their quality control and cell line development workflow.”
“We are very pleased with our collaboration with Cergentis, a highly innovative company providing services and kits to improve the efficiency of cell line development. With Genedata Selector we now provide a solution that fully supports the deployment of their TLA technology,” said Othmar Pfannes, Ph.D., Founder and CEO of Genedata. “TLA, together with Genedata Selector, enables our customers to scale up their cell line development processes and generate results of the highest quality. This is another example of how Genedata—together with other technology leaders—supports our customers in the biopharma industry to increase the efficiency of R&D.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.